Anolignan B: a bioactive compound from the roots of Terminalia sericea.
Antibacterial bioassay-guided fractionation of an ethyl acetate root extract of Terminalia sericea led to the isolation of anolignan B. The isolated compound was further tested for anti-inflammatory activity using the cyclooxygenase enzyme assays (COX-1 and COX-2) and for potential mutagenic effects using the Ames test. In the antibacterial test, anolignan B showed activity against both Gram-positive and Gram-negative bacteria. The minimum inhibitory concentration values obtained (MIC) ranged from 3.8 microg/ml against Bacillus subtilis (Gram-positive) to 31 microg/ml against Escherichia coli (Gram-negative). In the anti-inflammatory assays, anolignan B showed activity against both COX-1 (IC(50) = 1.5 mM) and COX-2 (IC(50) = 7.5 mM) enzymes. No potential mutagenic effects were observed in the Salmonella microsome assay (TA98). Isolation of anolignan B from Terminalia sericea as well as the antibacterial and anti-inflammatory activities observed in this study has not been reported previously.
Eldeen
Ibrahim M S
IM
Research Centre for Plant Growth and Development, School of Biological and Conservation Sciences, University of KwaZulu-Natal Pietermaritzburg, Scottsville, South Africa.
Elgorashi
Esameldin E
EE
Mulholland
Dulcie A
DA
van Staden
Johannes
J
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D017705:Lignans / Q000494:pharmacology* / Q000633:toxicity; D009152:Mutagenicity Tests; D018517:Plant Roots / Q000737:chemistry*; D029766:Terminalia / Q000737:chemistry*
D000900:Anti-Bacterial Agents; D016861:Cyclooxygenase Inhibitors; D017705:Lignans; C090326:anolignan B